Dr. Doris Rouse is vice president of Global Health Technologies at RTI International and an adjunct professor at the Gillings School.
At RTI, she manages the coordination of diverse disciplines to address major global health needs. Her research interests include development of new drugs and drug therapies to combat antibiotic resistance and antimicrobial resistant strains of bacteria. She leads a multidisciplinary team of scientists providing the regulatory and drug development expertise to plan and manage the preclinical and clinical development of new drugs and devices. Over the past 16 years, this team has supported the National Institutes of Health, nonprofits, universities, and small businesses in advancing compounds from early discovery to clinical development and regulatory submission.
For the Health and Human Services Office of the Assistant Secretary for Planning and Evaluation, Dr. Rouse recently led a study on best practices of public-private partnerships for medical product development. She has led three Gates Foundation global health projects focused on developing and bringing to market new medical products for low- and middle-income countries. For example, she was co-PI of the Maternal and Neonatal Directed Assessment of Technology project that developed a decision-support model to identify the higher impact opportunities for improving maternal and neonatal health in low resource settings.
In her tenure as Director of the Center for Technology Applications at RTI, she managed technology assessment, outlicensing, and technology sourcing projects for numerous government and corporate clients.